Interferon-beta (IFN-β) and glatiramer acetate (GA), serving as first-line immunomodulatory agents for multiple sclerosis (MS), regulate the disease process through distinct mechanisms. This evidence concerns the gene IFNB1 and myeloid sarcoma.